Current Targeted Therapies in Breast Cancer: Clinical Applications in the Elderly Woman

Oncologist

Volumn 16, Issue 8, 2011, Pages 1144-1153

  Spano, Jean Philippe ^a   Falandry, Claire ^b   Chaibi, Pascal ^c   Freyer, Gilles ^d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITÉ DE LYON   (France)

^c Groupe Hospitalier de la Pitié Salpétrière Charles Foix   (France)

^d HOSPICES CIVILS DE LYON   (France)

Author keywords

Breast cancer; Elderly woman; Recommendations; Targeted therapy

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTIANEMIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CELECOXIB; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; LAPATINIB; LETROZOLE; MAYTANSINE; NERATINIB; PACLITAXEL; PERTUZUMAB; TAXANE DERIVATIVE; TRASTUZUMAB;

ADVANCED CANCER; ANEMIA; ANGINA PECTORIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER SCREENING; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DAILY LIFE ACTIVITY; DIARRHEA; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE OVEREXPRESSION; GENE TARGETING; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; INFECTION; LIFE EXPECTANCY; MORTALITY; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 80052255344     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0028     Document Type: Article

References (57)

1. Wildiers H, Kunkler I, Biganzoli L et al. Management of breast cancer in elderly individuals: Recommendations of the International Society of Geriatric Oncology. Lancet Oncol 2007;8:1101-1115.
2. Pal SK, Katheria V, Hurria A. Evaluating the older patient with cancer: Understanding frailty and the geriatric assessment. CA Cancer J Clin 2010;60: 120-132.
3. Balducci L, Extermann M. A practical approach to the older patient with cancer. Curr Probl Cancer 2001;25:6-76.
4. Hamerman D. Toward an understanding of frailty. Ann Intern Med 1999; 130:945-950.
5. Crivellari D, Spazzapan S, Puglisi F et al. Hormone therapy in elderly breast cancer patients with comorbidities. Crit Rev Oncol Hematol 2010; 73:92-98.
6. Pierga JY, Girre V, Laurence V et al. Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age. Breast 2004;13: 369-375.
7. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104-110.
8. Cutuli B, De Lafontan B, Vitali E et al. Breast conserving treatment (BCT) for stage I-II breast cancer in elderly women: Analysis of 927 cases. Crit Rev Oncol Hematol 2009;71:79-88.
9. Louwman WJ, Janssen-Heijnen ML, Houterman S et al. Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: A population-based study. Eur J Cancer 2005;41:779-785.
10. Molino A, Giovannini M, Auriemma A et al. Pathological, biological and clinical characteristics, and surgical management, of elderly women with breast cancer. Crit Rev Oncol Hematol 2006;59:226-233.
11. Durbecq V, Ameye L, Veys I et al. A significant proportion of elderly patients develop hormone-dependant "luminal-B" tumours associated with aggressive characteristics. Crit Rev Oncol Hematol 2008;67:80-92.
12. Schonberg MA, Marcantonio ER, Li D et al. Breast cancer among the oldest old: Tumor characteristics, treatment choices, and survival. J Clin Oncol 2010;28:2038-2045.
13. Aapro M, Monfardini S, Jirillo A et al. Management of primary and advanced breast cancer in older unfit patients (medical treatment). Cancer Treat Rev 2009;35:503-508.
14. Tse GM, Tan PH, Lau KM et al. Breast cancer in the elderly: A histological assessment. Histopathology 2009;55:441-451.
15. Okunade G, Green AR, Ying M et al. Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy. Crit Rev Oncol Hematol 2009;72:76-82.
16. Barthélémy P, Heitz D, Mathelin C et al. Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals. Crit Rev Oncol Hematol 2009; 72:S18.
17. Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341: 2061-2067.
18. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
19. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353: 1673-1684.
20. Pivot X, Villanueva C, Bazan F et al. How safe is bevacizumab for elderly patients? Crit Rev Oncol Hematol 2009;18:S10
21. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
22. Tu CM, Chu KM, Yang SP et al. Trastuzumab (Herceptin)-associated cardiomyopathy presented as new onset of complete left bundle-branch block mimicking acute coronary syndrome: A case report and literature review. Am J Emerg Med 2009;27:903.e1-e3.
23. Al-Dasooqi N, Bowen JM, Gibson RJ et al. Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. Invest New Drugs 2009;27:173-178.
24. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676.
25. Valachis A, Polyzos NP, Patsopoulos NA et al. Bevacizumab in metastatic breast cancer: A meta-analysis of randomized controlled trials. Breast Cancer Res Treat 2010;122:1-7.
26. Gray R, Bhattacharya S, Bowden C et al. Independent review of E2100: A phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009;27:4966-4972.
27. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-1239.
28. Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 2010;117:497-504.
29. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
30. Capri G, Chang J, Chen SC et al. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol 2010;21:474-480.
31. Britten CD, Finn RS, Bosserman LD et al. A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: A dual ErbB targeted approach. Clin Breast Cancer 2009;9:16-22.
32. Baselga J, Gelmon KA, Verma S et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28:1138-1144.
33. Krop IE, Beeram M, Modi S et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010;28:2698-2704.
34. Burris HA 3rd, Rugo HS, Vukelja SJ et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29:398-405.
35. Serrano C, Cortés J, Russillo M et al. Trastuzumab-related cardiotoxicity in the elderly: Which role for cardiovascular risk factors? Eur J Cancer Suppl 2009;7:216.
36. Baselga J, Perez EA, Pienkowski T et al. Adjuvant trastuzumab: A milestone in the treatment of HER-2-positive early breast cancer. The Oncologist 2006;11(suppl 1):4-12.
37. Procter M, Suter TM, de Azambuja E et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 2010;28:3422-3428.
38. Brain EGC. Anthracyclines in elderly cancer patient: A SIOG expert position paper. Crit Rev Oncol Hematol 2009;72:S13.
39. Baselga J, Bradbury I, Eidtmann H et al. First results of the NeoALTTO trial (BIG 01-06/EGF 106903): A phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer [abstract S3-3]. Presented at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8-12, 2010.
40. Jones S, Holmes FA, O'Shaughnessy J et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009;27:1177-1183.
41. Singletary SE, Robb GL, Hortobagyi GN. Advanced Therapy of Breast Disease, Second Edition. Hamilton, Canada: BC Decker, 2004:1-22.
42. Valero V, Forbes J, Pegram MD et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-geneamplified metastatic breast cancer (BCIRG 007 Study): Two highly active therapeutic regimens. J Clin Oncol 2011;29:149-156.
43. Pierga JY, Delaloge S, Espié M et al. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat 2010;122:429-437.
44. Glissmeyer M. Reviewing prognostic factors in breast cancer management. JAAPA 2007;20:42-46.
45. McKeage K, Perry CM. Trastuzumab: A review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002;62:209-243.
46. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004;22:322-329.
47. Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptorpositive metastatic breast cancer: Results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5529-5537.
48. Perez EA, Koehler M, Byrne J et al. Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008; 83:679-686.
49. Johnston S, Pippen J Jr, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27: 5538-5546.
50. Moreira C, Kaklamani V. Lapatinib and breast cancer: Current indications and outlook for the future. Expert Rev Anticancer Ther 2010;10:1171-1182.
51. Petrelli F, Barni S. Bevacizumab in advanced breast cancer: An opportunity as second-line therapy? Med Oncol 2010 Dec 14 [Epub ahead of print]. doi: 10.1007/s12032-010-9773-z.
52. Gligorov J, Namer M. Recommandations pour la pratique clinique, Nice, Saint-Paul-de-Vence: et de trois! Oncologie 2009;11:495-496.
53. Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299:914-924.
54. Costa RB, Kurra G, Greenberg L et al. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol 2010;21:2153-2160.
55. Lee CM, Szabo A, Schrieve DC et al. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA 2006;295:389-397.
56. Aapro M, Bernard-Marty C, Brain EG et al. Anthracycline cardiotoxicity in the elderly cancer patient: A SIOG expert position paper. Ann Oncol 2011; 22:257-267.
57. Burstein HJ, Sun Y, Dirix LY et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010;28:1301-1307.